Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non–small cell lung cancer: the RECAPC multicenter registry
By
Ricardo Brugés
Pedro Ramos
Milton Lombana
Anderson Osma
Néstor Llinás
Javier Cuello
Andrés Yepes
Ray Manneh
Anabelly Coronel
Rebeca Granadillo
Carolina López
Álvaro Osorio
Daniel Santa
Natalia Arango
William Mantilla
Diego Gómez
July 17, 2026
Clinical Scorecard: Molecular Profiling, Initial Treatment Approaches, and Survival Outcomes in Metastatic Non-Small Cell Lung Cancer: Insights from the Colombian RECAPC Multicenter Registry
At a Glance
Category Detail
Condition Metastatic Non-Small Cell Lung Cancer Key Mechanisms Molecular profiling and PD-L1 status guide treatment selection. Target Population Patients with metastatic non-small cell lung cancer in Colombia. Care Setting Colombian healthcare system, multicenter registry.
Key Highlights
Cohort included 585 patients with a mean age of 72 years. First-line treatment patterns included chemotherapy, immunotherapy, and targeted therapy. Overall survival differed significantly by driver group. Incomplete molecular characterization and treatment documentation were common. Age and ECOG performance status were associated with mortality. Guideline-Based Recommendations
Diagnosis
Molecular testing for actionable oncogenic drivers is recommended. Management
First-line treatment should be guided by PD-L1 expression and driver status. Monitoring & Follow-up
Monitor overall survival and treatment outcomes in patients. Risks
Higher mortality associated with not tested/unknown driver status. Patient & Prescribing Data
Patients with metastatic non-small cell lung cancer.
First-line therapies included chemotherapy alone (34.4%) and targeted therapy (26.7%).
Clinical Best Practices
Ensure comprehensive molecular profiling to guide treatment. Document first-line treatment regimens accurately. Address barriers to timely diagnosis and treatment in healthcare systems. Related Resources & Content
